ClinTec International India Announces Expansion of its Asian Operations
Complete the form below to unlock access to ALL audio articles.
Over the next quarter, strategic moves into South Korea, Taiwan, Malaysia and Indonesia will also take place. The expansion has also been strengthened by the recent appointment of several regional CRAs plus Mary Pan, Director South East Asia who has over 12 years international experience in clinical research.
ClinTec CEO, President and Founder, Dr Buttar commented, “Whilst other CROs have tended to acquire local companies in Asia Pacific to expand their geographical presence, ClinTec has remained true to its strategy of organic growth and employing its own local staff members and therefore guaranteeing the same ClinTec culture, values and international standards in the region from the start of its operations. This has also allowed us to offer clients a high degree of flexibility in choosing the most suitable personnel for their projects, aligning our growth with those of our clients. Following a decade of building a strong regional hub in Bangalore, India, we are now tactically located in further Asian countries to meet big pharma’s global need for core resources including talent, experience and a wealth of localised clinical research knowledge.”
ClinTec’s regional Asian hub was opened in Bangalore in 2002 and now employees over 40 staff members across all clinical research functions.
On the strategic expansion, ClinTec’s Director, Asia Pacific and Middle East & Africa commented, “ClinTec’s corporate development plans in Asia this year, have a strong focus on building capabilities in South East Asia. In the last three years we have doubled the number of employees in India and more importantly added on several functional verticals within this operation to attain full CRO service capabilities. Our foray into South East Asia is driven by the objective of mirroring this growth in operational capabilities by leveraging the strong clinical research expertise that exist in most countries in this region.”
In the current economic climate, pharmaceutical companies are searching for new ways of working and delivering global solutions. As such, they are increasingly looking to enter new markets where revenues have not yet been fully tapped, and for partnerships with global CROs capable of facilitating world-wide multicentre clinical research needs. In the past 2 years, ClinTec has entered 25 new countries worldwide and its success has been founded on global experience, combined with local knowledge.
